RARRES3 Expression Positively Correlated to Tumour Differentiation in Tissues of Colorectal Adenocarcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2003 Jul 3

PMID 12838316

Citations 11

Authors

R-Y Shyu

S-Y Jiang

J-M Chou

Y-L Shih

M-S Lee

J-C Yu

P-C Chao

Y-J Hsu

S-W Jao

Affiliations

Soon will be listed here.

Abstract

RARRES3 is a retinoid-inducible class II tumour-suppressor gene. This study analysed the expression of RARRES3 protein in normal, adenoma and carcinoma tissues of the colorectum and its correlation with tumour differentiation. The expression of RARRES3 protein in 151 paraffin-embedded colorectal tissues (11 distal normal mucosa, 20 adenoma and 120 colorectal adenocarcinoma) was determined by immunohistochemistry. RARRES3 protein was expressed in all 11 distal normal, 120 adjacent normal and 20 adenoma tissues. In distal normal tissues, RARRES3 protein was expressed at the highest levels in differentiated mucosal epithelial cells. Among 120 carcinoma tissues, RARRES3 protein was detected in 97.6% (40 out of 41), 79.4% (54 out of 68) and 17.3% (three out of 11) of well-, moderately and poorly differentiated tumours, respectively. The expression of RARRES3 protein was positively correlated to tumour differentiation (test for trend, P<0.0001). Also, levels of RARRES3 protein were found to be higher in the normal tissues adjacent to 14.6% (six out of 41), 51.5% (35 out of 68), and 90.1% (10 out of 11) of well-, moderately and poorly differentiated tumours, respectively. The decreases in tumour differentiation and RARRES3 expression were significantly correlated compared to the adjacent normal tissues (test for trend, P<0.0001). The prognostic implication of RARRES3 protein expression was studied in 107 tumour, and no statistical difference in survival was observed. The expression of RARRES3 protein was positively correlated to cellular differentiation of normal and adenocarcinoma tissues of the colorectum, which supports the role of RARRES3 in normal and malignant epithelial differentiation of colorectum. RARRES3 expression was decreased only in carcinoma tissue, which suggests that altered RARRES3 expression occurs late in colorectal carcinogenesis.

Citing Articles

A gene signature linked to fibroblast differentiation for prognostic prediction of mesothelioma.

Liu J, Lu Y, Liu Y, Zhang W, Xian S, Wang S Cell Biosci. 2024; 14(1):33.

PMID: 38462627 PMC: 10926647. DOI: 10.1186/s13578-023-01180-7.

Phospholipase A and acyltransferase 4/retinoic acid receptor responder 3 at the intersection of tumor suppression and pathogen restriction.

Zhao J, Yuan X, Luo R, Wang L, Gu W, Yamane D Front Immunol. 2023; 14:1107239.

PMID: 37063830 PMC: 10102619. DOI: 10.3389/fimmu.2023.1107239.

Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing.

Zhang M, Hu S, Min M, Ni Y, Lu Z, Sun X Gut. 2020; 70(3):464-475.

PMID: 32532891 PMC: 7873416. DOI: 10.1136/gutjnl-2019-320368.

Retinoic Acids in the Treatment of Most Lethal Solid Cancers.

Costantini L, Molinari R, Farinon B, Merendino N J Clin Med. 2020; 9(2).

PMID: 32012980 PMC: 7073976. DOI: 10.3390/jcm9020360.

Long noncoding RNA HCP5 suppresses skin cutaneous melanoma development by regulating gene expression via sponging miR-12.

Wei X, Gu X, Ma M, Lou C Onco Targets Ther. 2019; 12:6323-6335.

PMID: 31496735 PMC: 6698080. DOI: 10.2147/OTT.S195796.

References

Akiyama H, Hiraki Y, Noda M, Shigeno C, Ito H, Nakamura T . Molecular cloning and biological activity of a novel Ha-Ras suppressor gene predominantly expressed in skeletal muscle, heart, brain, and bone marrow by differential display using clonal mouse EC cells, ATDC5. J Biol Chem. 1999; 274(45):32192-7. DOI: 10.1074/jbc.274.45.32192. View

Husmann K, Sers C, Fietze E, Mincheva A, Lichter P, Schafer R . Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11-12. Oncogene. 1998; 17(10):1305-12. DOI: 10.1038/sj.onc.1202060. View

Duvic M, Helekar B, Schulz C, Cho M, DiSepio D, Hager C . Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Clin Cancer Res. 2000; 6(8):3249-59. View

Chung D . The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology. 2000; 119(3):854-65. DOI: 10.1053/gast.2000.16507. View

Deucher A, Nagpal S, Chandraratna R, Di Sepio D, Robinson N, Dashti S . The carboxy-terminal hydrophobic domain of TIG3, a class II tumor suppressor protein, is required for appropriate cellular localization and optimal biological activity. Int J Oncol. 2000; 17(6):1195-203. DOI: 10.3892/ijo.17.6.1195. View

Saukkonen K, Nieminen O, van Rees B, Vilkki S, HARKONEN M, Juhola M . Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res. 2001; 7(7):1923-31. View

Siegrist S, Feral C, Chami M, Solhonne B, Mattei M, Rajpert-De Meyts E . hH-Rev107, a class II tumor suppressor gene, is expressed by post-meiotic testicular germ cells and CIS cells but not by human testicular germ cell tumors. Oncogene. 2001; 20(37):5155-63. PMC: 1865474. DOI: 10.1038/sj.onc.1204658. View

Casanova B, de la Fuente M, Sanz L, Silva A, Garcia-Marco J, Garcia-Pardo A . The class II tumor-suppressor gene RARRES3 is expressed in B cell lymphocytic leukemias and down-regulated with disease progression. Leukemia. 2001; 15(10):1521-6. DOI: 10.1038/sj.leu.2402243. View

Huang S, Shyu R, Yeh M, Jiang S . The retinoid-inducible gene I: effect on apoptosis and mitogen-activated kinase signal pathways. Anticancer Res. 2002; 22(2A):799-804. View

10.

Auer R, Bertoni F, Jones C, Cotter F . The class II tumour suppressor gene RARRES3 maps to 11q12, not 11q23. Leukemia. 2002; 16(7):1396; author reply 1396-7. DOI: 10.1038/sj.leu.2402505. View

11.

Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, STEIN H . Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984; 133(4):1710-5. View

12.

Remmele W, Stegner H . [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987; 8(3):138-40. View

13.

Vogelstein B, Fearon E, Hamilton S, Kern S, Preisinger A, Leppert M . Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319(9):525-32. DOI: 10.1056/NEJM198809013190901. View

14.

Hajnal A, Klemenz R, Schafer R . Subtraction cloning of H-rev107, a gene specifically expressed in H-ras resistant fibroblasts. Oncogene. 1994; 9(2):479-90. View

15.

Shyu R, Jiang S, Huang S, Chang T, Wu K, Roffler S . Growth regulation by all-trans-retinoic acid and retinoic acid receptor messenger ribonucleic acids expression in gastric cancer cells. Eur J Cancer. 1995; 31A(2):237-43. DOI: 10.1016/0959-8049(94)00481-j. View

16.

Iizuka M, Sugiyama Y, Shiraishi M, Jones C, Sekiya T . Allelic losses in human chromosome 11 in lung cancers. Genes Chromosomes Cancer. 1995; 13(1):40-6. DOI: 10.1002/gcc.2870130107. View

17.

Gabra H, Taylor L, Cohen B, Lessels A, Eccles D, Leonard R . Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. Br J Cancer. 1995; 72(2):367-75. PMC: 2033969. DOI: 10.1038/bjc.1995.340. View

18.

. Recommendations for the reporting of resected large intestinal carcinomas. Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol. 1996; 106(1):12-5. DOI: 10.1093/ajcp/106.1.12. View

19.

Sager R . Expression genetics in cancer: shifting the focus from DNA to RNA. Proc Natl Acad Sci U S A. 1997; 94(3):952-5. PMC: 19620. DOI: 10.1073/pnas.94.3.952. View

20.

Sers C, Emmenegger U, Husmann K, Bucher K, Andres A, Schafer R . Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors. J Cell Biol. 1997; 136(4):935-44. PMC: 2132501. DOI: 10.1083/jcb.136.4.935. View